The GnRH-ant protocol avoids many side-effects associated with GnRH agonist (GnRH-a) regimens (flare-ups, hypo-estrogenic, long down-regulation period), and results in a lower incidence of patients developing severe ovarian hyperstimulation syndrome (OHSS) (2). The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.